Sana Biotechnology (SANA) Payables (2020 - 2026)
Sana Biotechnology (SANA) posted Payables of $2.1 million for Q1 2026, up 27.2% sequentially from $1.7 million in Q4 2025, and up 114.66% YoY from $989000.0 in Q1 2025.
Sana Biotechnology (SANA) Payables (2020 - 2026) Analysis & Trends
Sana Biotechnology has reported Payables for 7 years, with the latest figure at $2.1 million in Q1 2026.
- Quarterly Payables rose 114.66% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 million (up 114.66% YoY) and the FY2025 annual result came in at $1.7 million, down 67.97% from the prior year.
- Payables climbed to $2.1 million in Q1 2026 per SANA's latest filing, from $1.7 million in the prior quarter.
- Over five years, Payables peaked at $9.9 million in Q3 2023 and troughed at $989000.0 in Q1 2025.
- A 5-year average of $3.6 million and a median of $3.1 million in 2022 frame the typical range for Payables.
- The sharpest annual moves came in 2024 and 2025: Payables surged 161.14% in 2024, then tumbled 83.77% in 2025.
- Over 5 years, Payables stood at $2.9 million in 2022, then jumped by 43.79% to $4.1 million in 2023, then rose by 26.83% to $5.2 million in 2024, then slumped by 67.97% to $1.7 million in 2025, then rose by 27.2% to $2.1 million in 2026.
- According to Business Quant data, Payables over the past three periods registered $2.1 million, $1.7 million, and $1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Sana Biotechnology | 1.06 Bn | 1.06 Bn | - | 1.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.36 Mn |
| Mar 31, 2026 | 2.12 Mn |
| Dec 31, 2025 | 1.67 Mn |
| Sep 30, 2025 | 1.86 Mn |
| Jun 30, 2025 | 2.27 Mn |
| Mar 31, 2025 | 989,000.00 |
| Dec 31, 2024 | 5.21 Mn |
| Sep 30, 2024 | 2.99 Mn |
| Jun 30, 2024 | 3.82 Mn |
| Mar 31, 2024 | 6.10 Mn |
| Dec 31, 2023 | 4.11 Mn |
| Sep 30, 2023 | 9.93 Mn |
| Jun 30, 2023 | 3.09 Mn |
| Mar 31, 2023 | 2.33 Mn |
| Dec 31, 2022 | 2.86 Mn |
| Sep 30, 2022 | 3.99 Mn |
| Jun 30, 2022 | 3.08 Mn |
| Mar 31, 2022 | 4.77 Mn |
| Dec 31, 2021 | 2.22 Mn |
| Sep 30, 2021 | 3.95 Mn |